The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Entrada plans to initiate clinical testing of ENTR-601-44 in Duchenne MD patients amenable to exon 44 skipping later this year.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Alternative splicing (AS), a critical process for gene expression regulation, allows a single precursor ...

Its expansion is attributed to the treatment of ambulatory DMD patients. The Duchenne muscular dystrophy (DMD) market across ...

Computational prediction of gene structure is crucial for interpreting ... Expression-based systems that use only native alignments tend to produce exon-intron structures that are quite accurate.

The study focused on the regulation of BOLA3 exon 3 inclusion by HNRNPC and its impact on ESCC cell behavior. BOLA3, a protein involved in various cellular processes, has been implicated in cancer ...

which chief executive Doug Ingram said showed that the gene therapy was not cannibalising sales of its exon-skipping drugs. Ingram also said that Sarepta was making good progress with other areas ...

Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...